Other anti-serum and other blood types due to the resolution of anti-cancer drugs
HS Code: 3002120099
SECTION 6
PRODUCTS OF THE CHEMICAL OF ALLIED INDUSTRIES
CHAPTER 30
Pharmaceutical products
HEADING 3002
Human blood; animal blood prepared for therapeutic
HS Code Structure Breakdown
| Level | Code | Description |
|---|---|---|
| Section | 6 | PRODUCTS OF THE CHEMICAL OF ALLIED INDUSTRIES |
| Chapter | 30 | Pharmaceutical products |
| Heading | 3002 | Human blood; animal blood prepared for therapeutic |
| Subheading | 300212 | Other anti-serum and other blood types due to the resolution of anti-cancer drugs |
| Commodity | 3002120099 | Other anti-serum and other blood types due to the resolution of anti-cancer drugs |
HS Code 3002120099 for Other anti-serum and other blood types due to the resolution of anti-cancer drugs
Product Wiki
Other anti-serum and other blood types due to the resolution of anti-cancer drugs has a clear classification code under the Harmonized Commodity Description and Coding System (HS Code), serving as an essential basis for customs authorities worldwide to conduct trade statistics and levy tariffs.
Cross-border trade data shows that China holds a non-negligible market share in the manufacturing and export supply of Other anti-serum and other blood types due to the resolution of anti-cancer drugs, with its export volume maintaining a high level over the long term.
Governments and industry associations worldwide usually set different market access standards, quality certifications, and environmental requirements for the import and export of Other anti-serum and other blood types due to the resolution of anti-cancer drugs.
With technological advancements and the diversification of market demands, the scope of application for Other anti-serum and other blood types due to the resolution of anti-cancer drugs continues to expand, driving the development of related industries.
Currently, the global supply-demand balance of Other anti-serum and other blood types due to the resolution of anti-cancer drugs is profoundly affected by macroeconomic fluctuations and geopolitics, with market prices and trade flows exhibiting cyclical variations.
Partner



Our licenses

China

HK MSO License

Singapore

UK API License

Netherlands

US MSB

CA MSB

AU RSP

